X4 Pharmaceuticals Inc (XFOR) - Total Liabilities
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has total liabilities worth $101.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore XFOR cash generation efficiency to assess how effectively this company generates cash.
X4 Pharmaceuticals Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how X4 Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check XFOR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
X4 Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canaan Inc
NASDAQ:CAN
|
USA | $165.52 Million |
|
Kelly Services A Inc
NASDAQ:KELYA
|
USA | $1.27 Billion |
|
DSC Investment Inc
KQ:241520
|
Korea | ₩43.38 Billion |
|
Ace Pillar Co Ltd
TW:8374
|
Taiwan | NT$2.11 Billion |
|
Argo Global Listed Infrastructure Ltd
AU:ALI
|
Australia | AU$16.31 Million |
|
Tus-Design Group Co Ltd Class A
SHE:300500
|
China | CN¥1.52 Billion |
|
RMR Group Inc
NASDAQ:RMR
|
USA | $272.28 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down X4 Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see X4 Pharmaceuticals Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how X4 Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for X4 Pharmaceuticals Inc (2015–2024)
The table below shows the annual total liabilities of X4 Pharmaceuticals Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $124.30 Million | +29.26% |
| 2023-12-31 | $96.16 Million | +17.94% |
| 2022-12-31 | $81.53 Million | +54.53% |
| 2021-12-31 | $52.76 Million | +5.38% |
| 2020-12-31 | $50.07 Million | +59.07% |
| 2019-12-31 | $31.48 Million | +118.54% |
| 2018-12-31 | $14.40 Million | -36.12% |
| 2017-12-31 | $22.55 Million | -64.86% |
| 2016-12-31 | $64.17 Million | +46.39% |
| 2015-12-31 | $43.83 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more